Biopharma shatters quarterly deal record with $90.4B Q2 haul
· amanda lanier
AI Briefing
- • Biopharma deal value reached $170.11 billion in H1 2026, highest on record by a wide margin.
- • Q2 2026 deal value surpassed Q4 2024's $80.65 billion, setting a new record high.
- • Q1 2026 deal value was $79.71 billion, contributing to the overall H1 total.
Context
Biopharma deal value for the first half of 2026 reached $170.11 billion, surpassing the previous record high of $139.35 billion in the first half of 2025. The first quarter contributed $79.71 billion to this total, while the second quarter saw a significant increase to $90.4 billion.
The second quarter's deal value of $90.4 billion is the highest single quarter on record, exceeding the $80.65 billion seen in the fourth quarter of 2024. This increase represents a 22% rise from the first half of 2025.
Advertisement